Upcoming Earnings: Q2 '26
Estimated EPS
-$0.27
Estimated Rev
$0.32M
• Reported GAAP EPS of -$0.14 up 72.00% YoY • Reported revenue of $0.35M down -60.75% YoY • Evogene expects full-year 2026 cash usage to be approximately $8.5 million to $9.5 million, compared with approximately $14.4 million in 2025 and approximately $20.5 million in 2024, with further reductions targeted.
Bullish Takeaway
Evogene successfully executed a strategic transformation by streamlining operations and reducing costs, while simultaneously achieving technological progress in its AI platforms and expanding its portfolio of active drug development collaborations.
Bearish Takeaway
Evogene reported decreased quarterly revenues, increased net financing expenses compared to the prior year period, and faces ongoing structural risks related to reliance on third-party partners for its critical research activities.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.27 | -- | -- | N/A |
Q1 '26 | -$0.27 | -$0.60 | -122.22% | MISSED |
Q4 '25 | -$0.26 | -$0.61 | -134.21% | MISSED |
Q3 '25 | -$0.41 | $0.44 | 208.40% | BEAT |
Q2 '25 | -$0.63 | -$0.50 | 20.63% | BEAT |